Rawcliffe Adrian
SEC Form 4 insider trading activity
Rawcliffe Adrian has filed 3 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Aug 14, 2026.
On the most recent filing, Rawcliffe Adrian is listed as Director at Wave Life Sciences, Inc. Inside the rolling window, Rawcliffe Adrian reported no open-market purchases and 3 open-market sales totaling $807K in WVE. The largest disclosed transaction in the window is a sale of 42,000 WVE shares on Dec 8, 2025, worth $630K.
Companies traded
Other insiders at WVE
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$807K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Rawcliffe Adrian made?
Rawcliffe Adrian has filed 3 SEC Form 4 filings (4 transaction rows) across 1 company since 2025.
Which companies does Rawcliffe Adrian trade?
Rawcliffe Adrian has filed SEC Form 4 disclosures for 1 company, including WVE.
When was Rawcliffe Adrian's most recent SEC Form 4 filing?
Rawcliffe Adrian's most recent SEC Form 4 filing on Tracefour is dated Aug 14, 2026.
What is Rawcliffe Adrian's total buy and sell value in the current window?
Inside the rolling retention window, Rawcliffe Adrian bought $0 and sold $807K based on SEC Form 4 filings.
What was Rawcliffe Adrian's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 42,000 WVE shares on 2025-12-08, worth $630K, per SEC Form 4 filings.